Chugai Pharmaceutical Co., Ltd.
https://www.chugai-pharm.co.jp/english/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chugai Pharmaceutical Co., Ltd.
Finance Watch: Dementia Discovery Fund’s Behr Sees Early Investments Reviving Neuroscience Interest
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.
NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II
NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.
J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Chugai Pharma Europe
- Chugai Pharma Taiwan Ltd.
- C&C Research Laboratories